Home Pipeline

Overview

MacroGenics has a diverse portfolio of proprietary product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or co-promotion rights in the U.S. or more broadly.

Program (Target)
Indications
Pre-IND Phase 1 Phase 2 Phase 3 Partner Our Commercial Rights
Oncology
Margetuximab (HER2) Green Cross Worldwide,
except Korea
Breast (3+) “SOPHIA”
Gastric (+pembrolizumab)
Breast (1-2+)
Enoblituzumab (B7–H3) Worldwide
Solid Tumors (mono.)
Solid Tumors (+ipi.)
Solid Tumors (+pembro.)
MGD006 (CD123 x CD3) Servier North America,
Japan, Korea, India
AML/MDS
MGD007 (gpA33 x CD3) Servier North America,
Japan, Korea, India
Colorectal
MGD011 (CD19 x CD3) Janssen U.S. Co-Promote1
B-cell Malignancies
MGD009 (B7-H3 x CD3) Worldwide
Solid Tumors
MGA012 Worldwide
Solid Tumors/Heme
MGD013 (PD-1 x LAG-3) Worldwide
Solid Tumors/Heme
AUTOIMMUNE & INFECTIOUS DISEASES
Teplizumab (CD3) NIDDK/NIH Worldwide
Type 1 Diabetes Prev.
MGD010 (CD32B x CD79B) Takeda U.S. Co-Promote2
Autoimmune Disorders
MGD014 (HIV x CD3) NIAID/NIH Worldwide
HIV

Oncology
Breast (3+) “SOPHIA”
Pre-IND Phase 1 Phase 2 Phase 3

Gastric (+pembrolizumab)
Pre-IND Phase 1 Phase 2 Phase 3

Breast (1-2+)
Pre-IND Phase 1 Phase 2 Phase 3

PartnerGreen Cross
Our Commercial RightsWorldwide, except Korea
Solid Tumors (mono.)
Pre-IND Phase 1 Phase 2 Phase 3

Solid Tumors (+ipi.)
Pre-IND Phase 1 Phase 2 Phase 3

Solid Tumors (+pembro.)
Pre-IND Phase 1 Phase 2 Phase 3

Our Commercial RightsWorldwide
AML/MDS
Pre-IND Phase 1 Phase 2 Phase 3

 
PartnerServier
Our Commercial RightsNorth America, Japan, Korea, India
Colorectal
Pre-IND Phase 1 Phase 2 Phase 3

 
PartnerServier
Our Commercial RightsNorth America, Japan, Korea, India
B-cell Malignancies
Pre-IND Phase 1 Phase 2 Phase 3

   
PartnerJanssen
Our Commercial RightsU.S. Co-Promote1
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3

   
Our Commercial RightsWorldwide
Solid Tumors/Heme
Pre-IND Phase 1 Phase 2 Phase 3

   
Our Commercial RightsWorldwide
Solid Tumors/Heme
Pre-IND Phase 1 Phase 2 Phase 3

   
Our Commercial RightsWorldwide
AUTOIMMUNE & INFECTIOUS DISEASES
Type 1 Diabetes Prev.
Pre-IND Phase 1 Phase 2 Phase 3

 
PartnerNIDDK/NIH
Our Commercial RightsWorldwide
Autoimmune Disorders
Pre-IND Phase 1 Phase 2 Phase 3

   
PartnerTakeda
Our Commercial RightsU.S. Co-Promote2
HIV
Pre-IND Phase 1 Phase 2 Phase 3

     
PartnerNIAID/NIH
Our Commercial RightsWorldwide

(1) Option for U.S. co-promote; may elect to fund portion of late-stage development in exchange for U.S. and Canada profit share.
(2) Option for U.S. co-promote; may elect to fund portion of Phase 3 development in exchange for North American profit share.

mAb DART

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close